Role of IL13 genetic polymorphism in the development of bronchial asthma in children

Bronchial asthma is a multifactorial disease, with both environmental factors and genetic predisposal affecting its development. A number of gene associations have been obtained between polymorphisms of cytokine genes produced by different types of immune cells and asthma development. Interleukin-13 is involved in allergic inflammation, increased bronchial hypersensitivity, regulation of eosinophil levels and IgE production by B cells, thus making it promising for studying IL13 gene polymorphisms in bronchial asthma coupled to development of the disease. The aim of this study was to investigate possible association between asthma and IL13 rs1800925 polymorphism in the children of Caucasian origin in Eastern Siberia. Four groups of patients with asthma were examined (mean age 12.8±1.2 years): with a controlled (n = 95) and uncontrolled course (n = 107), with severe (n = 71) and moderate severity (n = 131) diseases. The control group consisted of healthy individuals: children (n = 33) and adults (n = 102). DNA was isolated with sorbent method; genotyping was carried out using RT-PCR using specific oligonucleotide primers and fluorescent TaqMan probes. The allele and genotype frequencies were compared by the χ-square test using an online calculator. The odds ratio (OR) with a 95% confidence interval (CI) was performed to link genetic markers with pathological phenotypes. The CT IL13 rs1800925 genotype was shown to be associated with moderate asthma and cases of uncontrollable clinical course, whereas the TT genotype was associated with severe asthma. Thus, rs1800925 polymorphism of IL13 gene (the T* variant is known to be associated with increased IL-13 expression) may be associated with bronchial asthma in children. Our data are consistent with results of other authors. E.g., Liu Z. et al. revealed an association between rs1800925 IL13 and the risk of developing asthma in children, with CT and TT genotypes being more common in the patient group. Radhakrishnan A. et al., was studied rs1800925 IL13 in adult population of Malaysia and found that the T* allele frequency in the group of patients significantly exceeds the frequency of this allele in the control group. Thus, the results of our study showed that IL13 rs1800925 polymorphism is associated with bronchial asthma in children, especially, with level of its control and severity of the disease.

1. Smolnikova M.V., Freidin M.B., Smirnova S.V. Cytokine genes as genetic markers of atopic bronchial asthma with a controlled and uncontrolled course. Meditsinskaya immunologiya = Medical Immunology (Russia), 2017, Vol. 5, no. 19, pp. 597-604. (In Russ.) doi: 10.15789/1563-0625-2017-5-605-614.

2. Chernyak B.A., Vorzheva I.I. Agonists of beta2-adrenergic receptors in the treatment of bronchial asthma: issues of efficacy and safety. Consilium Medicum, 2006, Vol. 8, no. 10, pp. 66-72. (In Russ.)

3. Beghe B., Hall I.P., Parker S.G., Moffatt M.F., Wardlaw A., Connolly M.J., Fabbri L.M., Ruse C., Sayers I. Polymorphisms in IL13 pathway genes in asthma and chronic obstructive pulmonary disease. Allergy, 2010, Vol. 65, no. 4, pp. 474-481.

4. Corren J. Role of interleukin-13 in asthma. Curr. Allergy Asthma Rep., 2013, Vol. 13, no. 5, pp. 415-420.

5. Cui L., Jia J., Ma C.F., Li S.Y., Wang Y.P., Guo X.M., Li Q., Yu H.B., Liu W.H., Gao L.B. IL-13 polymorphisms contribute to the risk of asthma: a meta-analysis. Clin. Biochem., 2012, Vol. 45, no. 4-5, pp. 285-288.

6. Georas S.N., Gue J., Fanis U.D., Casolaro V. T-helper cell type-2 regulation in allergic disease. Eur. Respir. J., 2005, Vol. 26, no. 6, pp. 933-947.

7. Hunninghake G.M., Soto-Quiros M.E., Avila L., Su J., Murphy A., Demeo D.L., Ly N.P., Liang C., Sylvia J.S., Klanderman B.J., Lange C., Raby B.A., Silverman E.K., Celedon J.C. Polymorphisms in IL13, total IgE, eosinophilia, and asthma exacerbations in childhood. J. Allergy Clin. Immunol., 2007, Vol. 120, no. 1, pp. 84-90.

8. Liu Z., Li P., Wang J., Fan Q., Yan P., Zhang X., Han B. A meta-analysis of IL-13 polymorphisms and pediatric asthma risk. Med. Sci.Monit., 2014, Vol. 20, pp. 2617-2623.

9. Maier L.M., Howson J.M., Walker N., Spickett G.P., Jones R.W., Ring S.M., McArdle W.L., Lowe C.E., Bailey R., Payne F., Todd J.A., Strachan D.P. Association of IL13 with total IgE: evidence against an inverse association of atopy and diabetes. J. Allergy Clin. Immunol., 2006, Vol. 117, no. 6, pp. 1306-1313.

10. Mei Q., Qu J. Interleukin-13 +2044 G/A and +1923C/T polymorphisms are associated with asthma susceptibility in Asians: a meta-analysis. Medicine, 2017, Vol. 96, no. 51, e9203. doi: 10.1097/MD.0000000000009203.

11. Moffatt M.F., Gut I.G., Demenais F., Strachan D.P., Bouzigon E., Heath S., von Mutius E., Farrall M., Lathrop M. A large-scale, consortium-based genomewide association study of asthma. N. Engl. J. Med., 2010, Vol. 363, no. 13, pp. 1211-1221.

12. Radhakrishnan A.K., Raj V.L., Tan L.K., Liam C.K. Single nucleotide polymorphism in the promoter of the human interleukin-13 gene is associated with asthma in Malaysian adults. Biomed Res. Int., 2013, Vol. 2013, 981012. doi: 10.1155/2013/981012.

13. Rael E.L., Lockey R.F. Interleukin-13 signaling and its role in asthma. World Allergy Organ. J., 2011, Vol. 4, no. 3, pp. 54-64.

14. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol. Rev., 2004, Vol. 202, pp. 175-190.

15. Zhu Z., Homer R., Wang Z., Chen Q., Geba G., Wang J., Zhang Y., Elias J. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest., 1999, Vol. 103, no. 6, pp. 779-788.